User profiles for Yusef Badi

Yusef Badi

BenevolentAI, Imperial College London NHLI
Verified email at ic.ac.uk
Cited by 292

[HTML][HTML] Sputum ACE2, TMPRSS2 and FURIN gene expression in severe neutrophilic asthma

NZ Kermani, WJ Song, Y Badi, A Versi, Y Guo… - Respiratory …, 2021 - Springer
Background Patients with severe asthma may have a greater risk of dying from COVID-19
disease. Angiotensin converting enzyme-2 (ACE2) and the enzyme proteases, …

Sputum macrophage diversity and activation in asthma: role of severity and inflammatory phenotype

A Tiotiu, N Zounemat Kermani, Y Badi, S Pavlidis… - Allergy, 2021 - Wiley Online Library
Background Macrophages control innate and acquired immunity, but their role in severe
asthma remains ill‐defined. We investigated gene signatures of macrophage subtypes in the …

Development of therapeutic splice-switching oligonucleotides

P Disterer, A Kryczka, Y Liu, YE Badi, JJ Wong… - Human gene …, 2014 - liebertpub.com
Synthetic splice-switching oligonucleotides (SSOs) target nuclear pre-mRNA molecules to
change exon splicing and generate an alternative protein isoform. Clinical trials with two …

Crucial role for lung iron level and regulation in the pathogenesis and severity of asthma

…, OR Carroll, D Trinder, HL Tay, YE Badi… - European …, 2020 - Eur Respiratory Soc
Accumulating evidence highlights links between iron regulation and respiratory disease.
Here, we assessed the relationship between iron levels and regulatory responses in clinical …

Association of differential mast cell activation with granulocytic inflammation in severe asthma

A Tiotiu, Y Badi, NZ Kermani, M Sanak… - American journal of …, 2022 - atsjournals.org
Rationale: Mast cells (MCs) play a role in inflammation and both innate and adaptive
immunity, but their involvement in severe asthma (SA) remains undefined. Objectives: We …

IL1RAP expression and the enrichment of IL‐33 activation signatures in severe neutrophilic asthma

YE Badi, B Salcman, A Taylor, B Rana, NZ Kermani… - Allergy, 2023 - Wiley Online Library
Background Interleukin (IL)‐33 is an upstream regulator of type 2 (T2) eosinophilic
inflammation and has been proposed as a key driver of some asthma phenotypes. Objective To …

Mapping atopic dermatitis and anti–IL-22 response signatures to type 2–low severe neutrophilic asthma

YE Badi, AB Pavel, S Pavlidis, JH Riley, S Bates… - Journal of allergy and …, 2022 - Elsevier
Background Transcriptomic changes in patients who respond clinically to biological therapies
may identify responses in other tissues or diseases. Objective We sought to determine …

[HTML][HTML] Localization of Neuropeptide Gene Expression in Larvae of an Echinoderm, the Starfish Asterias rubens

…, EA Odekunle, M Zandawala, Y Badi… - Frontiers in …, 2016 - frontiersin.org
Neuropeptides are an ancient class of neuronal signaling molecules that regulate a variety
of physiological and behavioral processes in animals. The life cycle of many animals …

Airway expression of SARS-CoV-2 receptor, ACE2, and proteases, TMPRSS2 and furin, in severe asthma

NZ Kermani, WJ Song, A Lunt, Y Badi, A Versi, Y Guo… - medRxiv, 2020 - medrxiv.org
Background Patients with severe asthma may have a greater risk of dying from COVID-19
disease caused by SARS-CoV-2 virus. Angiotensin converting enzyme 2 (ACE2) receptor and …

Is Fezakinumab, an anti-IL22 antibody, a putative novel therapy for a subset of severe asthma?

Y Badi, AB Pavel, JH Riley, KF Chung… - 2019 - Eur Respiratory Soc
Background: Antibody-based therapies against Type 2 targets have been introduced for
severe eosinophilic asthma. Atopic dermatitis (AD) and asthma have similar inflammatory …